Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 11:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 89 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetic Neuropathic Pain Clear all
Completed Phase 1Phase 2 Interventional

Efficacy of Inhaled Cannabis in Diabetic Painful Peripheral Neuropathy

NCT00781001
View directory record Official record
Conditions
Painful Diabetic Neuropathy
Interventions
Cannabis
Drug
Lead sponsor
Center for Medicinal Cannabis Research
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Oct 3, 2026, 11:31 PM EDT
Recruiting Phase 2 Interventional

SPENDD: Quantitative Sensory Testing and Analgesic Response for Painful Peripheral Neuropathy.

NCT06614322
View directory record Official record
Conditions
Painful Peripheral Neuropathy, Diabetic Peripheral Neuropathic Pain (DPN), Chemotherapy Induced Peripheral Neuropathy (CIPN), Idiopathic Peripheral Neuropathy
Interventions
Pregabalin, Duloxetine, Placebo
Drug · Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 80 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Boston, Massachusetts • New York, New York • Rochester, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 3, 2026, 11:31 PM EDT
Active, not recruiting Not applicable Interventional

Optimization of NIBS for Diabetic Neuropathy Neuropathic Pain

NCT03625752
View directory record Official record
Conditions
Diabetic Neuropathies, Chronic Pain
Interventions
Active Comparator: Active tDCS + Active TUS, Sham
Device
Lead sponsor
Case Western Reserve University
Other
Eligibility
40 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Chicago, Illinois • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 3, 2026, 11:31 PM EDT
Completed Phase 4 Interventional

Tolerability of Switching to Duloxetine for the Management of Diabetic Nerve Pain

NCT00266643
View directory record Official record
Conditions
Diabetic Neuropathy, Painful
Interventions
duloxetine hydrochloride
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
18
States / cities
Phoenix, Arizona • Fort Myers, Florida • Tallahassee, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2007 · Synced Oct 3, 2026, 11:31 PM EDT
Completed Phase 2 Interventional Results available

A Study In Patients With Neuropathic Pain From Diabetic Peripheral Neuropathy (DPN)

NCT00643760
View directory record Official record
Conditions
Neuropathy, Diabetic
Interventions
Placebo, GEn 1200mg/day, GEn 2400mg/day, GEn 3600mg/day, Pregabalin
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
18 Years and older
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
90
States / cities
Alabaster, Alabama • Birmingham, Alabama • Dothan, Alabama + 81 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2013 · Synced Oct 3, 2026, 11:31 PM EDT
Not listed Phase 2 Interventional

A Clinical Outcomes Study to Measure Reduction in Pain and Numbness During Administration of an Amino Acid Formulation in Subjects Diagnosed With Peripheral Neuropathy

NCT01537705
View directory record Official record
Conditions
Diabetic Neuropathy, Chemotherapy Induced Neuropathy, HIV Neuropathy, Trauma Induced Neuropathy
Interventions
Neuron012703 (Medical Food)
Drug
Lead sponsor
Targeted Medical Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2012 · Synced Oct 3, 2026, 11:31 PM EDT
Not listed Phase 2 Interventional

Using Cannabidiol to Treat Diabetic Peripheral Neuropathy of the Feet

NCT04679545
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
CBD, Placebo
Drug
Lead sponsor
Pure Green
Industry
Eligibility
21 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Bloomfield Township, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 3, 2026, 11:31 PM EDT
Recruiting Phase 1 Interventional

MAD Study to Assess the Safety, Tolerability, PKs and Efficacy of YJ001 for Spray Use in Patients With DPNP

NCT06361108
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
YJ001 for Spray Use, Placebo of YJ001 for Spray Use
Drug
Lead sponsor
Zhejiang Hanmai Pharmaceutical Technology Co., Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Fredericksburg, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Oct 3, 2026, 11:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study on the Safety of BAY1817080 How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given to Participants With Moderate Renal Impairment and End Stage Renal Disease Requiring Dialysis Compared With Matched Participants With Normal Renal Function

NCT04471337
View directory record Official record
Conditions
Endometriosis Related Pain, Overactive Bladder, Diabetic Neuropathic Pain, Refractory or Unexplained Chronic Cough
Interventions
BAY1817080
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 79 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Oct 3, 2026, 11:31 PM EDT
Completed Phase 2 Interventional

Omnitram Safety and Efficacy in the Treatment of Diabetic Neuropathy

NCT03664921
View directory record Official record
Conditions
Diabetic Neuropathies, Neuropathic Pain, Pain, Chronic
Interventions
Omnitram Oral Tablet, Placebo Oral Tablet
Drug
Lead sponsor
Syntrix Biosystems, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Anaheim, California • Cerritos, California • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2021 · Synced Oct 3, 2026, 11:31 PM EDT
Terminated Phase 3 Interventional Results available

A Placebo Controlled, Randomized, Double Blind Trial of Milnacipran for the Treatment of Idiopathic Neuropathy Pain

NCT01288937
View directory record Official record
Conditions
Idiopathic Peripheral Neuropathy
Interventions
Milnacipran, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Oct 3, 2026, 11:31 PM EDT
Not listed Phase 4 Interventional

Bi-Axial Rotating Magnetic Field Therapy in Refractory Neuropathic Foot Pain Secondary to Diabetic Peripheral Neuropathy

NCT00123136
View directory record Official record
Conditions
Diabetic Neuropathies
Interventions
foot energizer
Device
Lead sponsor
Weintraub, Michael I., MD, FACP, FAAN
Individual
Eligibility
18 Years to 90 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Briarcliff, New York
Source: ClinicalTrials.gov public record
Updated Jul 4, 2006 · Synced Oct 3, 2026, 11:31 PM EDT
Recruiting Phase 3 Interventional

Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy

NCT06628908
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
Suzetrigine, Placebo (matched to SUZ), Pregabalin, Placebo (matched to Pregabalin)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
76
States / cities
Anniston, Alabama • Birmingham, Alabama • Daphne, Alabama + 68 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 3, 2026, 11:31 PM EDT
Completed Phase 4 Interventional Results available

An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain

NCT00385671
View directory record Official record
Conditions
Diabetic Neuropathy, Painful
Interventions
duloxetine hydrochloride, pregabalin, gabapentin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
5
States / cities
Torrance, California • Cromwell, Connecticut • Staten Island, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2011 · Synced Oct 3, 2026, 11:31 PM EDT
Withdrawn Phase 2 Interventional

Laser Therapy for Diabetic Peripheral Neuropathic Pain

NCT02328911
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
Laser treatment, Sham treatment
Device
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 28, 2015 · Synced Oct 3, 2026, 11:31 PM EDT
Completed Phase 2 Interventional

Study of the Safety and Efficacy of RGH-896 in Patients With Diabetic Peripheral Neuropathic Pain

NCT00838799
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
RGH-896, pregabalin, placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 75 Years
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
54
States / cities
Birmingham, Alabama • Mesa, Arizona • Tempe, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2011 · Synced Oct 3, 2026, 11:31 PM EDT
Terminated Phase 4 Interventional

Ranolazine for Diabetic Peripheral Neuropathic Pain (DPNP)

NCT02156336
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Horizons International Peripheral Group
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Fairhope, Alabama • Houma, Louisiana • Lafayette, Louisiana
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 3, 2026, 11:31 PM EDT
Completed Not applicable Interventional

Treatment of Painful Diabetic Neuropathy With Photon Stimulation

NCT00539175
View directory record Official record
Conditions
Diabetic Neuropathy, Painful, Diabetic Neuralgia, Diabetic Polyneuropathy, Diabetic Mononeuropathy
Interventions
infrared light, infrared light; placebo
Device
Lead sponsor
East Bay Institute for Research and Education
Other
Eligibility
18 Years to 85 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Martinez, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2007 · Synced Oct 3, 2026, 11:31 PM EDT
Terminated Phase 4 Interventional Results available

Three Way Interaction Between Gabapentin, Duloxetine, and Donepezil in Patients With Diabetic Neuropathy

NCT00619983
View directory record Official record
Conditions
Diabetic Neuropathic Pain, Chronic Low Back Pain
Interventions
donepezil, duloxetine, donepezil 2.5 mg and duloxetine 30mg, placebo, gabapentin
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 3, 2026, 11:31 PM EDT
Terminated Phase 2 Interventional

A 52-Week Study of Bicifadine in Patients With Chronic Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

NCT00597649
View directory record Official record
Conditions
Chronic Peripheral Neuropathy Pain in Diabetics
Interventions
Bicifadine
Drug
Lead sponsor
XTL Biopharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Paducah, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 30, 2009 · Synced Oct 3, 2026, 11:31 PM EDT
Completed Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of OraVescent Fentanyl Citrate Treatment for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Noncancer-Related Chronic Pain

NCT00343733
View directory record Official record
Conditions
Pain
Interventions
OraVescent Fentanyl
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
21
States / cities
Hot Springs, Arkansas • Los Gatos, California • Oxnard, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 3, 2026, 11:31 PM EDT
Withdrawn Not applicable Interventional

Exercise Induced Hypoalgesia Diabetes

NCT05296642
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy, Diabetic Peripheral Neuropathic Pain
Interventions
Moderate Cycling, Personalized Tourniquet System
Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 25, 2022 · Synced Oct 3, 2026, 11:31 PM EDT
Completed Phase 2 Interventional

A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)

NCT06203002
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
Placebo (blinded), LX9211 (blinded)
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
108
States / cities
Anniston, Alabama • Birmingham, Alabama • Daphne, Alabama + 91 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2025 · Synced Oct 3, 2026, 11:31 PM EDT
Not listed Phase 1Phase 2 Interventional

Diabetic Neuropathic Pain Relief, 6 Weeks Dosage Sublingual Water-soluble CBD/PEA

NCT05766969
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
CBD/PEA, Placebo
Drug
Lead sponsor
Pure Green Pharmaceuticals Inc.
Industry
Eligibility
21 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Southfield, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 13, 2023 · Synced Oct 3, 2026, 11:31 PM EDT